Tristel logo

TSTL - Tristel News Story

292.5p -2.5  -0.8%

Last Trade - 18/10/19

Small Cap
Market Cap £130.4m
Enterprise Value £126.3m
Revenue £26.2m
Position in Universe 913th / 1855

Tristel PLC - Issue of Equity

Fri 17th May, 2019 1:58pm
RNS Number : 4464Z
Tristel PLC
17 May 2019


Tristel plc

("Tristel" or the "Company")

Issue of Equity

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that, following the exercise of options by employees, it has issued and allotted 30,000 new ordinary shares of 1 penny each in the Company ("Ordinary Shares"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 23 May 2019. 

The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following the exercise of options, the Company's issued share capital consists of 44,539,823 Ordinary Shares. Accordingly, the figure of 44,539,823 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:       


Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780 or

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07854 391 303


Tel: 020 7220 0500

Geoff Nash / Giles Rolls, Corporate Finance

Alice Lane, ECM



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.